Erlotinib Completed Phase 2 Trials for Prostate Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00272038Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer
NCT00203424Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
NCT00087035Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer